266 publications
Sort by: Date / Relevance
Conditional inclusion procedure for medicinal products
This document describes the conditional inclusion procedure for orphan drugs, conditionals and exceptionals.
Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
Zorginstituut Nederland has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult patients with ...
International strategic agenda 2020 National Health Care Institute
When performing its tasks, the National Health Care Institute (Zorginstituut Nederland, or ZIN) participates with various other ...
Oral semaglutide (Rybelsus®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Zorginstituut Nederland has completed its assessment whether oral semaglutide (Rybelsus®) is interchangeable with a product that ...
Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions
Zorginstituut Nederland has completed its assessment whether pentosan polysulfate sodium (Elmiron®) is interchangeable with a ...
12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group
Zorginstituut Nederland has completed its assessment whether 12 SQ-HDM SLIT (Itulazax®) is interchangeable with a product that ...
Olaparib (Lynparza®) for the maintenance treatment of adult patients with carcinoma of the ovaries, tubes or peritoneum
Zorginstituut Nederland has completed its assessment whether olaparib (Lynparza®) as a monotherapy for the maintenance treatment ...
Trientine tetrahydrochloride (Cuprior®) the treatment of Wilson’s disease
Zorginstituut Nederland has completed its assessment whether trientine tetrahydrochloride (Cuprior®) is interchangeable with a ...
Hydroquinine (Inhibin®) for patients with nocturnal muscle cramps
Zorginstituut Nederland has assessed whether hydroquinine (Inhibin®) should be included in the medication reimbursement system ...
Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations
Zorginstituut Nederland has completed its assessment whether voretigene neparvovec (Luxturna®) for the treatment of vision loss ...